280 related articles for article (PubMed ID: 24418912)
1. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
[TBL] [Abstract][Full Text] [Related]
2. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
3. Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer.
Mitsunari K; Miyata Y; Asai A; Matsuo T; Shida Y; Hakariya T; Sakai H
Transl Res; 2016 Sep; 175():116-28. PubMed ID: 27140699
[TBL] [Abstract][Full Text] [Related]
4. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
8. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
[TBL] [Abstract][Full Text] [Related]
9. RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype.
Yang D; Kedei N; Li L; Tao J; Velasquez JF; Michalowski AM; Tóth BI; Marincsák R; Varga A; Bíró T; Yuspa SH; Blumberg PM
Cancer Res; 2010 Oct; 70(20):7905-17. PubMed ID: 20876802
[TBL] [Abstract][Full Text] [Related]
10. Function of RasGRP3 in the formation and progression of human breast cancer.
Nagy Z; Kovács I; Török M; Tóth D; Vereb G; Buzás K; Juhász I; Blumberg PM; Bíró T; Czifra G
Mol Cancer; 2014 Apr; 13():96. PubMed ID: 24779681
[TBL] [Abstract][Full Text] [Related]
11. miR-196a-mediated downregulation of p27
Zhan B; Huang L; Chen Y; Ye W; Li J; Chen J; Yang S; Jiang W
Prostate; 2020 Sep; 80(12):1024-1037. PubMed ID: 32628792
[TBL] [Abstract][Full Text] [Related]
12. Tumor Suppressor Role and Clinical Significance of the
Liang YX; Liang YK; Zou ZH; Zhuo YJ; Ye JH; Zhu XJ; Cai ZD; Lin ZY; Mo RJ; Wu SL; Zhang YQ; Zhong WD
Dis Markers; 2022; 2022():8724035. PubMed ID: 35548776
[TBL] [Abstract][Full Text] [Related]
13. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
14. CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.
Bauman TM; Ewald JA; Huang W; Ricke WA
BMC Cancer; 2015 Jul; 15():549. PubMed ID: 26209327
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
Huang M; Narita S; Tsuchiya N; Ma Z; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Carcinogenesis; 2011 Nov; 32(11):1589-96. PubMed ID: 21828059
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
Babasaki T; Sentani K; Sekino Y; Kobayashi G; Thang Pham Q; Katsuya N; Akabane S; Taniyama D; Hayashi T; Shiota M; Oue N; Teishima J; Matsubara A; Yasui W
Cancer Med; 2021 Aug; 10(16):5574-5588. PubMed ID: 34240817
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy.
Bi XC; Liu JM; Zheng XG; Xian ZY; Feng ZW; Lou YX; Zhong WD; Wu CL
Clin Invest Med; 2011 Dec; 34(6):E358. PubMed ID: 22129926
[TBL] [Abstract][Full Text] [Related]
19. PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.
Kao KR; Popadiuk P; Thoms J; Aoki S; Anwar S; Fitzgerald E; Andrews P; Voisey K; Gai L; Challa S; He Z; Gonzales-Aguirre P; Simmonds A; Popadiuk C
J Clin Pathol; 2018 May; 71(5):402-411. PubMed ID: 28924059
[TBL] [Abstract][Full Text] [Related]
20. UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy.
Wan X; Yang S; Huang W; Wu D; Chen H; Wu M; Li J; Li T; Li Y
J Exp Clin Cancer Res; 2016 Feb; 35():34. PubMed ID: 26884069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
